A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
Status:
Completed
Trial end date:
2020-03-20
Target enrollment:
Participant gender:
Summary
This study is looking at the effect of semaglutide on subjects with nonalcoholic fatty liver
disease.This study is comparing the change in early stages of scar tissue in the liver and
fat deposition in the liver in people taking semaglutide and placebo (a dummy medicine).
Participants will either get semaglutide or placebo; which treatment participants get is
decided by chance. Semaglutide is a medicine under clinical investigation. That means that
the medicine has not yet been approved by the authorities. Participants will need to
self-inject medicine once daily for 72 weeks. The medicine should be injected under the skin
in the stomach, thigh or upper arm.
There are about 3 weeks before participants start the study medicine and 7 weeks after you
stop it. The study will last for about 82 weeks in total.
Participants will have 12 clinic visits, 6 phone calls and 4 visits to an MRI centre.
The study includes MRI scans of the stomach. The MRI scans will take place at a different
location. Participants will be excluded from the study if the study doctor thinks that there
are risks for participants health. Women cannot take part if pregnant, breast-feeding or plan
to become pregnant during the study period.